43 phenotypes from 7 alleles in 8 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Hsd11b1tm1.1Awhi/Hsd11b1tm1.1Awhi involves: 129S1/Sv * 129X1/SvJ * C57BL/6	normal growth/size/body region phenotype	J:207713
	normal homeostasis/metabolism phenotype	J:207713
	increased food intake	J:207713
Hsd11b1tm1.1Ggla/Hsd11b1tm1.1Ggla involves: 129P2/OlaHsd	abnormal enzyme/coenzyme activity	J:141273
	decreased circulating corticosterone level	J:189059
	enlarged adrenal glands	J:189059
Hsd11b1tm1.1Ggla/Hsd11b1tm1.1Ggla involves: 129P2/OlaHsd * C57BL/6 * FVB/N	enlarged adrenal glands	J:189132
	normal muscle phenotype	J:189132
Hsd11b1tm1.2Awhi/Hsd11b1tm1.2Awhi Tg(Nes-cre)1Kln/0 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	abnormal food intake	J:207713
	normal growth/size/body region phenotype	J:207713
	normal homeostasis/metabolism phenotype	J:207713
Hsd11b1tm1.2Tuck/Hsd11b1tm1.2Tuck involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal circulating insulin level	J:203302
	abnormal epididymal fat pad morphology	J:203302
	decreased susceptibility to weight gain	J:203302
	normal homeostasis/metabolism phenotype	J:203302
Hsd11b1tm1a(KOMP)Wtsi/Hsd11b1+ involves: C57BL/6Jcl * C57BL/6N	abnormal corticosterone level	J:214146
	decreased collagen level	J:214146
	increased circulating corticosterone level	J:214146
	increased fibroblast proliferation	J:214146
Hsd11b1tm1a(KOMP)Wtsi/Hsd11b1tm1a(KOMP)Wtsi involves: C57BL/6Jcl * C57BL/6N	abnormal corticosterone level	J:214146
	abnormal fibroblast proliferation	J:214146
	decreased collagen level	J:214146
	increased circulating corticosterone level	J:214146
	increased fibroblast proliferation	J:214146
	increased subcutaneous adipose tissue amount	J:214146
Hsd11b1tm1Ggla/Hsd11b1tm1Ggla Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: 129P2/OlaHsd * C57BL/6 * DBA	abnormal eating behavior	J:189059
	abnormal glucose tolerance	J:189059
	decreased circulating corticosterone level	J:189059
	decreased circulating insulin level	J:189059
	enlarged adrenal glands	J:189059
	normal growth/size/body region phenotype	J:189059
	normal homeostasis/metabolism phenotype	J:189059
	increased circulating HDL cholesterol level	J:189059
	normal liver/biliary system phenotype	J:189059
Hsd11b1tm1Yko/Hsd11b1tm1Yko B6.129P2(Cg)-Hsd11b1tm1Yko	abnormal abdominal fat pad morphology	J:89080
	abnormal epididymal fat pad morphology	J:89080
	decreased circulating LDL cholesterol level	J:89080
	improved glucose tolerance	J:89080
	increased circulating HDL cholesterol level	J:89080
Hsd11b1tm1Yko/Hsd11b1tm1Yko involves: 129P2/OlaHsd * MF1	abnormal abdominal fat pad morphology	J:89080
	abnormal amniotic fluid composition	J:80523
	abnormal brainstem morphology	J:68825
	abnormal circulating cholesterol level	J:72402
	abnormal corticosterone level	J:45085, J:67184
	abnormal epididymal fat pad morphology	J:89080
	abnormal glucose homeostasis	J:37960
	abnormal hippocampus morphology	J:68825
	abnormal lipid homeostasis	J:72402
	abnormal lung development	J:80523
	abnormal pulmonary alveolus morphology	J:80523
	abnormal spatial learning	J:68825
	absent alveolar lamellar bodies	J:80523
	decreased alveolar lamellar body number	J:80523
	decreased circulating glucose level	J:37960, J:45085
	decreased circulating triglyceride level	J:72402
	decreased surfactant secretion	J:80523
	enlarged adrenal glands	J:37960, J:45085
	hepatic steatosis	J:72402
	improved glucose tolerance	J:72402
	increased circulating cholesterol level	J:72402
	increased circulating HDL cholesterol level	J:72402
	increased liver glycogen level	J:45085
	small alveolar lamellar bodies	J:80523